<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//TaxonX//DTD Taxonomic Treatment Publishing DTD v0 20100105//EN" "../../nlm/tax-treatment-NS0.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:tp="http://www.plazi.org/taxpub" article-type="research-article" dtd-version="3.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">89</journal-id>
      <journal-id journal-id-type="index">urn:lsid:arphahub.com:pub:CCBBD2E1-BDAF-5702-AE4B-0E4910A4C7D6</journal-id>
      <journal-title-group>
        <journal-title xml:lang="en">Pharmacia</journal-title>
        <abbrev-journal-title xml:lang="en">PHAR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0428-0296</issn>
      <issn pub-type="epub">2603-557X</issn>
      <publisher>
        <publisher-name>Bulgarian Pharmaceutical Scientific Society</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3897/pharmacia.68.e62465</article-id>
      <article-id pub-id-type="publisher-id">62465</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="scientific_subject">
          <subject>Pharmaceutics</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Impact of the manufacturing technique on the dissolution-enhancement functionality of PEG4000 in Cilostazol tablets</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" xlink:type="simple" corresp="yes">
          <name name-style="western">
            <surname>Sawafta</surname>
            <given-names>Obada</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <email xlink:type="simple">obada_sawafta@yahoo.com</email>
          <uri content-type="orcid">https://orcid.org/0000-0003-1852-4390</uri>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple" corresp="no">
          <name name-style="western">
            <surname>Alhadid</surname>
            <given-names>Sonia</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple" corresp="no">
          <name name-style="western">
            <surname>Awwad</surname>
            <given-names>Izz Aldeen Abu</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple" corresp="no">
          <name name-style="western">
            <surname>Migdadi</surname>
            <given-names>Eman</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple" corresp="no">
          <name name-style="western">
            <surname>Aljaberi</surname>
            <given-names>Ahmad</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="A1">
        <label>1</label>
        <addr-line content-type="verbatim">Department of Pharmaceutical Sciences and Pharmaceutics, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan</addr-line>
        <institution>Applied Science Private University</institution>
        <addr-line content-type="city">Amman</addr-line>
        <country>Jordan</country>
      </aff>
      <aff id="A2">
        <label>2</label>
        <addr-line content-type="verbatim">Tabuk Pharmaceutical Research Company, Amman, Jordan</addr-line>
        <institution>Tabuk Pharmaceutical Research Company</institution>
        <addr-line content-type="city">Amman</addr-line>
        <country>Jordan</country>
      </aff>
      <author-notes>
        <fn fn-type="corresp">
          <p>Corresponding author: Obada Sawafta (<email xlink:type="simple">obada_sawafta@yahoo.com</email>)</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>22</day>
        <month>02</month>
        <year>2021</year>
      </pub-date>
      <volume>68</volume>
      <issue>1</issue>
      <fpage>243</fpage>
      <lpage>250</lpage>
      <uri content-type="arpha" xlink:href="http://openbiodiv.net/BC74B306-DF2D-5DE4-BE91-29923B55AE78">BC74B306-DF2D-5DE4-BE91-29923B55AE78</uri>
      <history>
        <date date-type="received">
          <day>25</day>
          <month>12</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>01</day>
          <month>02</month>
          <year>2021</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Obada Sawafta, Sonia Alhadid, Izz Aldeen Abu Awwad, Eman Migdadi, Ahmad Aljaberi</copyright-statement>
        <license license-type="creative-commons-attribution" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <label>Abstract</label>
        <p>Cilostazol was selected as poorly-soluble model drug to investigate the impact of the manufacturing method on the excipient functionality of PEG4000 at various levels. Powder blends were prepared by direct compression (<abbrev xlink:title="direct compression" id="ABBRID0EDE">DC</abbrev>), wet granulation (<abbrev xlink:title="wet granulation" id="ABBRID0EHE">WG</abbrev>) and hot-melt extrusion (<abbrev xlink:title="hot-melt extrusion" id="ABBRID0ELE">HME</abbrev>). Characteristics of these blends and their compressed tablets were investigated by standard techniques. Solid-state characterization was carried out using differential scanning calorimetry (<abbrev xlink:title="differential scanning calorimetry" id="ABBRID0EPE">DSC</abbrev>). While <abbrev xlink:title="direct compression" id="ABBRID0ETE">DC</abbrev> trials were found with no significant differences, <abbrev xlink:title="wet granulation" id="ABBRID0EXE">WG</abbrev> and <abbrev xlink:title="hot-melt extrusion" id="ABBRID0E2E">HME</abbrev> showed contrasting enhancement and retardation effects regarding the dissolution profile of Cilostazol tablets depending on the level of PEG4000 incorporated. The optimal enhancement of dissolution was obtained at 10% w/w PEG4000 for tablets prepared by <abbrev xlink:title="hot-melt extrusion" id="ABBRID0E6E">HME</abbrev>. <abbrev xlink:title="differential scanning calorimetry" id="ABBRID0EDF">DSC</abbrev> analysis indicated that no solid solutions were formed at such low levels of PEG4000during processing by either manufacturing techniques. Consequently, the wetting functionality and dissolution enhancement of PEG4000 was revealed to be level- and manufacturing method dependent.</p>
      </abstract>
      <kwd-group>
        <label>Keywords</label>
        <kwd>Hot-melt extrusion</kwd>
        <kwd>Cilostazol</kwd>
        <kwd>PEG4000</kwd>
        <kwd>Dissolution</kwd>
        <kwd>excipient functionality</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="Introduction" id="SECID0EPF">
      <title>Introduction</title>
      <p>APIs with poor solubility represent 40% of the marketed drug entities and almost 90% of molecules in the pipeline of discovery (<xref ref-type="bibr" rid="B18">Repka et al. 2008</xref>; <xref ref-type="bibr" rid="B7">Kalepu and Nekkanti 2015</xref>). For many drug substances, conventional methods of formulating tablets dosage forms such as direct compression and wet granulation provide clinically effective therapy while keeping the required balance of pharmacodynamic and pharmacokinetic profiles without any effect on patient’s safety. However, there are some limitations to the use the conventional methods of formulation with poorly soluble drugs. Moreover, few APIs imply the necessary characteristics during the tableting process. To overcome the poor solubility as well as the poor physical characteristics of some APIs, tablets manufacturing could imply complex processes or rather different manufacturing approaches.</p>
      <p>Hot-melt extrusion (<abbrev xlink:title="hot-melt extrusion" id="ABBRID0E6F">HME</abbrev>), is an example of such techniques that were proven as a viable technique in pharmaceutical manufacturing. <abbrev xlink:title="hot-melt extrusion" id="ABBRID0EDG">HME</abbrev> technique has been demonstrated to be applicable in preparing immediate release granules, sustained-release tablets, transdermal and trans-mucosal drug delivery systems (<xref ref-type="bibr" rid="B16">Regev et al. 2019</xref>; <xref ref-type="bibr" rid="B17">Ren et al. 2019</xref>; <xref ref-type="bibr" rid="B23">Yang et al. 2019</xref>; <xref ref-type="bibr" rid="B20">Tang et al. 2019</xref>; <xref ref-type="bibr" rid="B19">Sanoufi et al. 2020</xref>). Several pharmaceutical products manufactured by <abbrev xlink:title="hot-melt extrusion" id="ABBRID0E2G">HME</abbrev> technique are now commercially available such as Nurofen, Isoptin SR-E and Kaletra (<xref ref-type="bibr" rid="B10">Maniruzzaman et al. 2012</xref>). The vast majority of <abbrev xlink:title="hot-melt extrusion" id="ABBRID0EDH">HME</abbrev> studies for solubility enhancement were trying to solve the poor solubility problem by changing the molecular level of the <abbrev xlink:title="Active Pharmaceutical Ingredients" id="ABBRID0EHH">API</abbrev> and forming solid dispersions by incorporating hydrophilic carriers (<xref ref-type="bibr" rid="B9">Leuner and Dressman 2000</xref>; <xref ref-type="bibr" rid="B1">Albers et al. 2009</xref>; <xref ref-type="bibr" rid="B8">Kalivoda et al. 2012</xref>; <xref ref-type="bibr" rid="B21">Weatherley et al. 2013</xref>; <xref ref-type="bibr" rid="B24">Zi et al. 2019</xref>). Different types of dispersions can be obtained using melt extrusion of a drug within a polymer in a binary mixture. i.e. the drug could be dispersed molecularly within the carrier (polymer) or exists on its amorphous or crystalline original phase. In such an approach, a high polymer to drug ratio is usually required to maintain the physical stability of the solid extrudates whether the drug is solubilized or dispersed (<xref ref-type="bibr" rid="B13">Patil et al. 2016</xref>).</p>
      <p>However, the usefulness of <abbrev xlink:title="hot-melt extrusion" id="ABBRID0EGAAC">HME</abbrev> technique in enhancing drug dissolution simply through improved wettability and solubilization upon using hydrophilic polymers at a low polymer to drug ratio was overlooked. In addition, few studies have put <abbrev xlink:title="hot-melt extrusion" id="ABBRID0EKAAC">HME</abbrev> into comparison with other conventional methods regarding their effect on the solubility and dissolution for formulations incorporating hydrophilic polymers. Therefore, the aim of this work was to study and clarify the effect of PEG4000 as a hydrophilic polymer on the dissolution of Cilostazol as a model poorly soluble drug in a tablet dosage form (Figure <xref ref-type="fig" rid="F1">1</xref>). Additionally, this work aimed to clarify how the different manufacturing technologies may contribute to Cilostazol dissolution without changing the crystalline form of the <abbrev xlink:title="Active Pharmaceutical Ingredients" id="ABBRID0ESAAC">API</abbrev>.</p>
      <fig id="F1" position="float" orientation="portrait">
        <object-id content-type="doi">10.3897/pharmacia.68.e62465.figure1</object-id>
        <object-id content-type="arpha">8257710E-1D0C-54E8-A1BA-18D773DD962B</object-id>
        <label>Figure 1.</label>
        <caption>
          <p>The chemical structure of (A) Cilostazol and (B) PEG4000. The average value of n in PEG4000 is 90.</p>
        </caption>
        <graphic xlink:href="pharmacia-68-e62465-g001.jpg" position="float" orientation="portrait" xlink:type="simple" id="oo_511699.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/511699</uri>
        </graphic>
      </fig>
    </sec>
    <sec sec-type="methods" id="SECID0ECBAC">
      <title>Methodology</title>
      <sec sec-type="Abbreviations" id="SECID0EGBAC">
        <title>Abbreviations</title>
        <p><abbrev xlink:title="direct compression" id="ABBRID0EMBAC">DC</abbrev>, Direct compression; <abbrev xlink:title="Differential scanning calorimetry" id="ABBRID0EQBAC">DSC</abbrev>, Differential scanning calorimetry; <abbrev xlink:title="Active Pharmaceutical Ingredients" id="ABBRID0EUBAC">API</abbrev>, Active Pharmaceutical Ingredients; <abbrev xlink:title="Carr’s index" id="ABBRID0EYBAC">CI</abbrev>, Carr’s index; <abbrev xlink:title="Generally regarded as safe" id="ABBRID0E3BAC">GRAS</abbrev>, Generally regarded as safe; <abbrev xlink:title="Hot-melt extrusion" id="ABBRID0EACAC">HME</abbrev>, Hot-melt extrusion; <abbrev xlink:title="Hydroxy-propyl-methyl-cellulose" id="ABBRID0EECAC">HPMC</abbrev>, Hydroxy-propyl-methyl-cellulose; <abbrev xlink:title="Particle Size Distribution" id="ABBRID0EICAC">PSD</abbrev>, Particle Size Distribution; <abbrev xlink:title="Polyethylene Glycol" id="ABBRID0EMCAC">PEG</abbrev>, Polyethylene Glycol; <abbrev xlink:title="Relative Standard Deviation" id="ABBRID0EQCAC">RSD</abbrev>, Relative Standard Deviation; <abbrev xlink:title="Standard Deviation" id="ABBRID0EUCAC">SD</abbrev>, Standard Deviation; <abbrev xlink:title="wet granulation" id="ABBRID0EYCAC">WG</abbrev>, Wet Granulation; <abbrev xlink:title="loss on drying" id="ABBRID0E3CAC">LOD</abbrev>, loss on drying.</p>
      </sec>
      <sec sec-type="Materials" id="SECID0EADAC">
        <title>Materials</title>
        <p>Cilostazol used in the study was produced by Cadila LTD Company (Ahmedabad, India), <abbrev xlink:title="Polyethylene Glycol" id="ABBRID0EGDAC">PEG</abbrev> 4000 was from by Seppic company (La Garenne-Colombes, France). Avicel PH102 was from FMC Corporation (Philadelphia, PA, USA). Lactose Monohydrate was from DFE Pharma Company (Tamil Nadu, India). Carmellose Calcium was from Nichirin Company (Hyōgo Prefecture, Japan). Colloidal Silicon Dioxide was from Evonik (Essen, Germany). Magnesium Stearate was from Merck (New Jersey, USA). Sodium lauryl sulfate was from Sigma Aldrich (St. Louis, MO, USA).</p>
      </sec>
      <sec sec-type="Direct compression process" id="SECID0EKDAC">
        <title>Direct compression process</title>
        <p>A standardized formula of Cilostazol tablets was prepared by <abbrev xlink:title="direct compression" id="ABBRID0EQDAC">DC</abbrev> technique using the composition of the prototype formula, named DC01 (Table <xref ref-type="table" rid="T1">1</xref>). The standard formula was performed without the incorporation of PEG4000. Briefly, Cilostazol was mixed with Lactose. The mixed blend was sieved through # 30 mesh sieve. Avicel PH102, colloidal silicon dioxide and carmellose calcium were de-lumped prior to addition by pre-sieving through # 30 mesh sieves. All of the components of each formulation were accurately weighed, mixed in a polyethylene bag for 10 minutes manually to obtain a uniform dry blend. Magnesium Stearate at 1% w/w level was added to the blend prepared above and the components were mixed for an additional 5 minutes. All other trials were accomplished in the same way but with addition of the hydrophilic polymers with the quantity specified in each formulation. PEG4000 flakes were milled using an automatic grinder (Sanyo blinder, Sanyo Electrics Co. LTD, Japan) prior to use. The tableting process involved a rotary compression machine (Cad-mackCambert Compression machine) equipped with rounded 9.0 mm in diameter punches and their die.</p>
        <table-wrap id="T1" position="float" orientation="portrait">
          <label>Table 1.</label>
          <caption>
            <p>The composition for Cilostazol tablets prepared by various manufacturing techniques.</p>
          </caption>
          <table id="TID0EK1AE" rules="all">
            <tbody>
              <tr>
                <th rowspan="1" colspan="1"/>
                <th rowspan="1" colspan="1">DC01</th>
                <th rowspan="1" colspan="1">DC02</th>
                <th rowspan="1" colspan="1">DC03/HME02</th>
                <th rowspan="1" colspan="1">DC04/HME03</th>
                <th rowspan="1" colspan="1">WG01</th>
                <th rowspan="1" colspan="1">WG02</th>
                <th rowspan="1" colspan="1">WG03</th>
                <th rowspan="1" colspan="1">WG04</th>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Material name</td>
                <td rowspan="1" colspan="1">w/w%</td>
                <td rowspan="1" colspan="1">w/w%</td>
                <td rowspan="1" colspan="1">w/w%</td>
                <td rowspan="1" colspan="1">w/w%</td>
                <td rowspan="1" colspan="1">w/w%</td>
                <td rowspan="1" colspan="1">w/w%</td>
                <td rowspan="1" colspan="1">w/w%</td>
                <td rowspan="1" colspan="1">w/w%</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Cilostazol</td>
                <td rowspan="1" colspan="1">33.33</td>
                <td rowspan="1" colspan="1">33.33</td>
                <td rowspan="1" colspan="1">33.33</td>
                <td rowspan="1" colspan="1">33.33</td>
                <td rowspan="1" colspan="1">33.33</td>
                <td rowspan="1" colspan="1">33.33</td>
                <td rowspan="1" colspan="1">33.33</td>
                <td rowspan="1" colspan="1">33.33</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Lactose Monohydrate</td>
                <td rowspan="1" colspan="1">16.67</td>
                <td rowspan="1" colspan="1">16.67</td>
                <td rowspan="1" colspan="1">16.67</td>
                <td rowspan="1" colspan="1">16.67</td>
                <td rowspan="1" colspan="1">16.67</td>
                <td rowspan="1" colspan="1">16.67</td>
                <td rowspan="1" colspan="1">16.67</td>
                <td rowspan="1" colspan="1">16.67</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Polyethylene Glycol 4000</td>
                <td rowspan="1" colspan="1">–</td>
                <td rowspan="1" colspan="1">5.0</td>
                <td rowspan="1" colspan="1">10.0</td>
                <td rowspan="1" colspan="1">20.0</td>
                <td rowspan="1" colspan="1">–</td>
                <td rowspan="1" colspan="1">5.0</td>
                <td rowspan="1" colspan="1">10.0</td>
                <td rowspan="1" colspan="1">20.0</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Purified Water*</td>
                <td rowspan="1" colspan="1">–</td>
                <td rowspan="1" colspan="1">–</td>
                <td rowspan="1" colspan="1">–</td>
                <td rowspan="1" colspan="1">–</td>
                <td rowspan="1" colspan="1">q.s**</td>
                <td rowspan="1" colspan="1">q.s**</td>
                <td rowspan="1" colspan="1">q.s**</td>
                <td rowspan="1" colspan="1">q.s**</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Avicel PH102</td>
                <td rowspan="1" colspan="1">46.0</td>
                <td rowspan="1" colspan="1">41.0</td>
                <td rowspan="1" colspan="1">36.0</td>
                <td rowspan="1" colspan="1">26.0</td>
                <td rowspan="1" colspan="1">46.0</td>
                <td rowspan="1" colspan="1">41.0</td>
                <td rowspan="1" colspan="1">36.0</td>
                <td rowspan="1" colspan="1">26.0</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Carmellose Calcium</td>
                <td rowspan="1" colspan="1">2.0</td>
                <td rowspan="1" colspan="1">2.0</td>
                <td rowspan="1" colspan="1">2.0</td>
                <td rowspan="1" colspan="1">2.0</td>
                <td rowspan="1" colspan="1">2.0</td>
                <td rowspan="1" colspan="1">2.0</td>
                <td rowspan="1" colspan="1">2.0</td>
                <td rowspan="1" colspan="1">2.0</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Colloidal Silicon Dioxide</td>
                <td rowspan="1" colspan="1">1.0</td>
                <td rowspan="1" colspan="1">1.0</td>
                <td rowspan="1" colspan="1">1.0</td>
                <td rowspan="1" colspan="1">1.0</td>
                <td rowspan="1" colspan="1">1.0</td>
                <td rowspan="1" colspan="1">1.0</td>
                <td rowspan="1" colspan="1">1.0</td>
                <td rowspan="1" colspan="1">1.0</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Mg Stearate</td>
                <td rowspan="1" colspan="1">1.0</td>
                <td rowspan="1" colspan="1">1.0</td>
                <td rowspan="1" colspan="1">1.0</td>
                <td rowspan="1" colspan="1">1.0</td>
                <td rowspan="1" colspan="1">1.0</td>
                <td rowspan="1" colspan="1">1.0</td>
                <td rowspan="1" colspan="1">1.0</td>
                <td rowspan="1" colspan="1">1.0</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Total</td>
                <td rowspan="1" colspan="1">100.0</td>
                <td rowspan="1" colspan="1">100.0</td>
                <td rowspan="1" colspan="1">100.0</td>
                <td rowspan="1" colspan="1">100.0</td>
                <td rowspan="1" colspan="1">100.0</td>
                <td rowspan="1" colspan="1">100.0</td>
                <td rowspan="1" colspan="1">100.0</td>
                <td rowspan="1" colspan="1">100.0</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>* Evaporated during the drying process, though it is not included in the final tablets weight. ** Sufficient quantity.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec sec-type="Wet granulation process" id="SECID0E2NAC">
        <title>Wet granulation process</title>
        <p>A standardized formula of Cilostazol tablets was prepared by <abbrev xlink:title="wet granulation" id="ABBRID0EBOAC">WG</abbrev> technique using the composition of the prototype formulation mentioned previously. This trial was named WG01. Cilostazol, Lactose Monohydrate, and PEG4000 were sieved through # 30 mesh and mixed for 10 minutes. The blend was granulated manually with Purified water until satisfactory massed granules were produced. The granules were dried in an oven at 40 °C to a loss on drying (<abbrev xlink:title="loss on drying" id="ABBRID0EFOAC">LOD</abbrev>) value less than 3.0% in order to get strong granules that aid the manufacturing process. The granules were milled using Sanyo grinder and then passed through # 30 mesh. Extra-granular components were added as described previously for the <abbrev xlink:title="direct compression" id="ABBRID0EJOAC">DC</abbrev> trials. Tablets were compressed as described before using a rotary compression machine equipped with the same tooling.</p>
      </sec>
      <sec sec-type="Hot-melt extrusion process" id="SECID0ENOAC">
        <title>Hot-melt extrusion process</title>
        <p>A dry physical blend of Cilostazol, PEG4000 polymer, and Lactose Monohydrate for each formulation was fed into the hopper of a vertical lab-scale single screw Microtruder (Model RCP-0375) with a screw diameter of 0.3750 inches and a working length to diameter ratio of 24 (Randcastle Extrusion Systems Inc., Cedar Grove, NJ, USA). A rod-shaped die was attached to the end of the barrel with a diameter of 4.0 mm. The trails were processed at a screw speed of 20 rpm and at 50, 60, 65, and 70 °C for zone 1, 2, 3, and the die, respectively. After cooling down to room temperature, the obtained extrudates were manually cut into small parts prior to milling by Sanyo grinder. The milled powder was passed through 30 # mesh sieve. The addition of extra-granular components and tableting followed the previously described procedures.</p>
      </sec>
      <sec sec-type="Bulk and tapped densities, Hausner Ratio, Carr’s index and angle of repose of powder blends" id="SECID0ESOAC">
        <title>Bulk and tapped densities, Hausner Ratio, Carr’s index and angle of repose of powder blends</title>
        <p>The bulk and tapped densities were measured for the final blends after processing by different formulation techniques. The bulk density was calculated by measuring the weight of a defined volume of each blend based on the following equation</p>
        <p>
          <mml:math id="M1">
            <mml:mtext> Bulk density </mml:mtext>
            <mml:mo>=</mml:mo>
            <mml:mfrac>
              <mml:mrow>
                <mml:mtext> Weight </mml:mtext>
                <mml:mo>(</mml:mo>
                <mml:mi>gm</mml:mi>
                <mml:mo>)</mml:mo>
              </mml:mrow>
              <mml:mrow>
                <mml:mtext> Volume </mml:mtext>
                <mml:mo>(</mml:mo>
                <mml:mi>ml</mml:mi>
                <mml:mo>)</mml:mo>
              </mml:mrow>
            </mml:mfrac>
          </mml:math>
        </p>
        <p>The tapped density was obtained by mechanically tapping a graduated cylinder containing the sample until little further volume change was observed. The tapped density was measured for the final tapped volume (V<sub>f</sub>) for a defined weight of blend as per the following equation:</p>
        <p>
          <mml:math id="M2">
            <mml:mtext> Tapped density </mml:mtext>
            <mml:mo>=</mml:mo>
            <mml:mfrac>
              <mml:mrow>
                <mml:mtext> Weight </mml:mtext>
                <mml:mo>(</mml:mo>
                <mml:mi>gm</mml:mi>
                <mml:mo>)</mml:mo>
              </mml:mrow>
              <mml:mrow>
                <mml:msub>
                  <mml:mi mathvariant="normal">V</mml:mi>
                  <mml:mi mathvariant="normal">f</mml:mi>
                </mml:msub>
                <mml:mo>(</mml:mo>
                <mml:mi>ml</mml:mi>
                <mml:mo>)</mml:mo>
              </mml:mrow>
            </mml:mfrac>
          </mml:math>
        </p>
        <p>The compressibility index or Carr’s index (<abbrev xlink:title="Carr’s index" id="ABBRID0E4OAC">CI</abbrev>) and the Hausner ratio are calculated from the unsettled apparent volume V<sub>0</sub> and the final tapped volume V<sub>f</sub> after no further volume changes occur according to the following equations:</p>
        <p>
          <mml:math id="M3">
            <mml:mi>CI</mml:mi>
            <mml:mo>=</mml:mo>
            <mml:mfrac>
              <mml:mrow>
                <mml:msub>
                  <mml:mi mathvariant="normal">V</mml:mi>
                  <mml:mn>0</mml:mn>
                </mml:msub>
                <mml:mo>-</mml:mo>
                <mml:msub>
                  <mml:mi mathvariant="normal">V</mml:mi>
                  <mml:mi mathvariant="normal">f</mml:mi>
                </mml:msub>
              </mml:mrow>
              <mml:msub>
                <mml:mi mathvariant="normal">V</mml:mi>
                <mml:mn>0</mml:mn>
              </mml:msub>
            </mml:mfrac>
            <mml:mo>×</mml:mo>
            <mml:mn>100</mml:mn>
            <mml:mo>%</mml:mo>
          </mml:math>
        </p>
        <p>
          <mml:math id="M4">
            <mml:mtext> Hausner ratio </mml:mtext>
            <mml:mo>=</mml:mo>
            <mml:mfrac>
              <mml:msub>
                <mml:mi>V</mml:mi>
                <mml:mn>0</mml:mn>
              </mml:msub>
              <mml:msub>
                <mml:mi>V</mml:mi>
                <mml:mi>f</mml:mi>
              </mml:msub>
            </mml:mfrac>
          </mml:math>
        </p>
        <p>Finally, the angle of repose was calculated by measuring the angle of the free surface of a pile of powder to the horizontal plane according to the following equation:</p>
        <p>
          <mml:math id="M5">
            <mml:mo>Tan</mml:mo>
            <mml:mo>(</mml:mo>
            <mml:mi>α</mml:mi>
            <mml:mo>)</mml:mo>
            <mml:mo>=</mml:mo>
            <mml:mfrac>
              <mml:mtext> Height </mml:mtext>
              <mml:mrow>
                <mml:mn>0</mml:mn>
                <mml:mo>.</mml:mo>
                <mml:mn>5</mml:mn>
                <mml:mtext> base </mml:mtext>
              </mml:mrow>
            </mml:mfrac>
          </mml:math>
        </p>
        <p>During all experiments, the height of the funnel was fixed at 2.5 cm. The diameters of the base formed were measured carefully. The powder of each formula passed through the funnel without any intervention. All of the cones formed were symmetrical.</p>
      </sec>
      <sec sec-type="Particle size distribution" id="SECID0EHPAC">
        <title>Particle size distribution</title>
        <p>Particle size distribution of different formulations was tested by laser diffraction technology. Enough quantity of the blend of each formulation was placed in the dry sampling part (Aero) of a Mastersizer 3000 (Malvern, model 3000, Worcestershire-UK). The powder was passed through the dry cell with a laser beam focused through a glass window inside the cell. Based on the diffracted laser beams, the instrument software provided the cumulated particle size distribution. D<sub>10</sub>, D<sub>50</sub>, and D<sub>90</sub> values were calculated for each formulation, where they represent 10%, 50%, and 90% volume of the particle mass diameter that is smaller than the size indicated, respectively.</p>
      </sec>
      <sec sec-type="Physical characterization of the tablets: weight, hardness, thickness and disintegration testing" id="SECID0ETPAC">
        <title>Physical characterization of the tablets: weight, hardness, thickness and disintegration testing</title>
        <p>Target hardness was set to be around 100 Newton for all the trials in order to exclude any possible effect on the dissolution profile except for factors were set by the study; i.e., polymer quantity and the method of formulation. Samples from the prepared formulations were randomly selected and tested for weight variation, crushing strength and thickness. The weight variation test was conducted by weighing 10 tablets from each formulation individually using a Mettler Toledo electronic lab balance. The individual tablet weights were compared to the average. The acceptance criterion for the weight variation is 5% from average weight (general chapter, USP40). The hardness and thickness of 4 tablets from each formulation were determined using a calibrated hardness tester; ERWEKA TBH300MD hardness tester (Langen, Germany). The force in Newton needed to break each tablet was recorded side by side to the thickness of each sample. The mean, <abbrev xlink:title="Standard Deviation" id="ABBRID0EZPAC">SD</abbrev> and <abbrev xlink:title="Relative Standard Deviation" id="ABBRID0E4PAC">RSD</abbrev> were calculated. Disintegration of 6 tablets of each trial was measured in a warmed tap water 37 °C temperature, using Electrolab Disintegration Tester (Electrolab, model ED-L2, India). The results from different characterization procedures were recorded and the mean value, <abbrev xlink:title="Standard Deviation" id="ABBRID0ECAAE">SD</abbrev> and <abbrev xlink:title="Relative Standard Deviation" id="ABBRID0EGAAE">RSD</abbrev> were calculated for each trial.</p>
      </sec>
      <sec sec-type="In-vitro dissolution" id="SECID0EKAAE">
        <title>In-vitro dissolution</title>
        <p>The dissolution was performed in a paddle apparatus with a stirring rate of 75 rpm in a medium consisted of 900 ml with 0.3% Sodium Lauryl Sulfate solution maintained at 37 ± 0.5 °C (USP 40). A Pharmatest dissolution system (Model PTW II; Hamburg, Germany) was used. Five milliliters of the test fluid were withdrawn manually at predetermined time interval (5, 10, 15, 20, 30, 45, and 60 minutes), passed through a 0.45-μm milli-pore glass filter and analyzed for Cilostazol at λ = 259 nm by means of a UV-VIS single-beam spectrophotometer (Model 9200; United Kingdom). At each sampling time, a pre-warmed equal volume of the test medium was replaced. All the measurements were performed in duplicates and the amount of Cilostazol released for 6 tablets per each formula was determined using a respective calibration curve.</p>
      </sec>
      <sec sec-type="Differential scanning calorimetry" id="SECID0EPAAE">
        <title>Differential scanning calorimetry</title>
        <p><abbrev xlink:title="differential scanning calorimetry" id="ABBRID0EVAAE">DSC</abbrev> technique was used in order to recognize any changes that could happen to the <abbrev xlink:title="Active Pharmaceutical Ingredients" id="ABBRID0EZAAE">API</abbrev> crystal form after incorporating into <abbrev xlink:title="hot-melt extrusion" id="ABBRID0E4AAE">HME</abbrev> system with the hydrophilic polymer. The <abbrev xlink:title="differential scanning calorimetry" id="ABBRID0EBBAE">DSC</abbrev> scans of the <abbrev xlink:title="Active Pharmaceutical Ingredients" id="ABBRID0EFBAE">API</abbrev>, each polymer, and the main filler were performed separately. Further combination of the <abbrev xlink:title="Active Pharmaceutical Ingredients" id="ABBRID0EJBAE">API</abbrev> with the main filler, with and without PEG4000 were tested by the <abbrev xlink:title="differential scanning calorimetry" id="ABBRID0ENBAE">DSC</abbrev> as well. Finally, <abbrev xlink:title="differential scanning calorimetry" id="ABBRID0ERBAE">DSC</abbrev> scans of the different extrudates were performed. A sample with a range of 5 to 10 mg of each trial was weighed inside the crucible, and then the crucible was sealed. The sample was inserted next to a reference crucible inside the <abbrev xlink:title="differential scanning calorimetry" id="ABBRID0EVBAE">DSC</abbrev> furnace maintained with N<sub>2</sub> inert gas flow of 100 cm/minute. The samples were scanned at a heat rate of 10 °C/minute from ambient temperature to 200 °C, except for lactose monohydrate sample which was scanned to 250 °C.</p>
      </sec>
    </sec>
    <sec sec-type="Results and discussion" id="SECID0E2BAE">
      <title>Results and discussion</title>
      <p>Tablets dosage form is the most convenient route of administration. In contrast, it has a main drawback regarding poor solubility for many APIs in the pharmaceutical pipeline. Hydrophilic polymers are expected to enhance the dissolution profile of poorly soluble drugs (<xref ref-type="bibr" rid="B22">Xu et al. 2007</xref>; <xref ref-type="bibr" rid="B11">Patel and Patel 2008</xref>). However, the magnitude of enhancement is dependent on the type and quantity of the hydrophilic polymer used as well as the principle method of formulation or manufacturing(<xref ref-type="bibr" rid="B6">Hashim et al. 2015</xref>; <xref ref-type="bibr" rid="B12">Patel et al. 2008</xref>).Understanding excipient functionality is a prerequisite for a successful product formulation development (<xref ref-type="bibr" rid="B2">Aljaberi et al. 2009</xref>; <xref ref-type="bibr" rid="B3">Aljaberi et al. 2013a</xref>, <xref ref-type="bibr" rid="B4">b</xref>). Therefore, a poorly soluble <abbrev xlink:title="Active Pharmaceutical Ingredients" id="ABBRID0E4CAE">API</abbrev>, Cilostazol, with very bad physical characteristics was selected for the purpose of this study. Various trials using <abbrev xlink:title="direct compression" id="ABBRID0EBDAE">DC</abbrev>, <abbrev xlink:title="wet granulation" id="ABBRID0EFDAE">WG</abbrev>, and <abbrev xlink:title="hot-melt extrusion" id="ABBRID0EJDAE">HME</abbrev> with the incorporation of PEG4000 at various levels were under analysis to illustrate the impact of manufacturing technique on the excipient functionality of this hydrophilic polymer.</p>
      <sec sec-type="Physical characteristics of the final blends" id="SECID0ENDAE">
        <title>Physical characteristics of the final blends</title>
        <p>The physical characteristics of each of the <abbrev xlink:title="direct compression" id="ABBRID0ETDAE">DC</abbrev>, <abbrev xlink:title="wet granulation" id="ABBRID0EXDAE">WG</abbrev>, <abbrev xlink:title="hot-melt extrusion" id="ABBRID0E2DAE">HME</abbrev> trials were measured as detailed in the experimental part and the results are summarized in Table <xref ref-type="table" rid="T2">2</xref>.The results show that <abbrev xlink:title="direct compression" id="ABBRID0EDEAE">DC</abbrev> method had low contribution with the physical characteristics of the blends i.e. the <abbrev xlink:title="Active Pharmaceutical Ingredients" id="ABBRID0EHEAE">API</abbrev> implied its bad nature over the blends of <abbrev xlink:title="direct compression" id="ABBRID0ELEAE">DC</abbrev> trials. Bad flow and sticky nature of the blend were the general characteristics of all the <abbrev xlink:title="direct compression" id="ABBRID0EPEAE">DC</abbrev> trials. No real enhancement for the flow upon incorporation of the polymers could be observed; even at the highest concentrations. The same could be seen with the <abbrev xlink:title="wet granulation" id="ABBRID0ETEAE">WG</abbrev> method when PEG4000 was not incorporated. WG01 was with the worst characteristics in <abbrev xlink:title="wet granulation" id="ABBRID0EXEAE">WG</abbrev> trials. However, it was better than all the <abbrev xlink:title="direct compression" id="ABBRID0E2EAE">DC</abbrev> trials. The incorporation of the polymer to the formulation had a positive effect on the flow of the powder. In agreement with the previously reported improvement of flowability and compactibility, <abbrev xlink:title="hot-melt extrusion" id="ABBRID0E6EAE">HME</abbrev> implied the best physical characteristics over all other trials (<xref ref-type="bibr" rid="B14">Pinho et al. 2018</xref>). Melting the polymeric material with vigorous mixing and compression, followed by milling resulted in a powder with better characteristics. <abbrev xlink:title="hot-melt extrusion" id="ABBRID0EHFAE">HME</abbrev> with PEG4000 was with slightly better results when compared to <abbrev xlink:title="wet granulation" id="ABBRID0ELFAE">WG</abbrev> with PEG4000 at the same level. The more the quantity of PEG4000 used, the less the difference between <abbrev xlink:title="wet granulation" id="ABBRID0EPFAE">WG</abbrev> and <abbrev xlink:title="hot-melt extrusion" id="ABBRID0ETFAE">HME</abbrev> in terms of physical characteristics of the final blends. It appears also that the more the quantity of the polymer used, the better the characteristics of the final blend (Table <xref ref-type="table" rid="T2">2</xref>)</p>
        <table-wrap id="T2" position="float" orientation="portrait">
          <label>Table 2.</label>
          <caption>
            <p>Physical characteristics for the Cilostazol Final blends.</p>
          </caption>
          <table id="TID0EIJAG" rules="all">
            <tbody>
              <tr>
                <th rowspan="1" colspan="1">Trial number</th>
                <th rowspan="1" colspan="1">DC01</th>
                <th rowspan="1" colspan="1">DC02</th>
                <th rowspan="1" colspan="1">DC03</th>
                <th rowspan="1" colspan="1">DC04</th>
                <th rowspan="1" colspan="1">WG01</th>
                <th rowspan="1" colspan="1">WG02</th>
                <th rowspan="1" colspan="1">WG03</th>
                <th rowspan="1" colspan="1">WG04</th>
                <th rowspan="1" colspan="1">HME02</th>
                <th rowspan="1" colspan="1">HME03</th>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Apparent Density (gm/ml)</td>
                <td rowspan="1" colspan="1">0.31</td>
                <td rowspan="1" colspan="1">0.32</td>
                <td rowspan="1" colspan="1">0.33</td>
                <td rowspan="1" colspan="1">0.34</td>
                <td rowspan="1" colspan="1">0.46</td>
                <td rowspan="1" colspan="1">0.46</td>
                <td rowspan="1" colspan="1">0.51</td>
                <td rowspan="1" colspan="1">0.51</td>
                <td rowspan="1" colspan="1">0.52</td>
                <td rowspan="1" colspan="1">0.60</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Tapped density (gm/ml)</td>
                <td rowspan="1" colspan="1">0.58</td>
                <td rowspan="1" colspan="1">0.56</td>
                <td rowspan="1" colspan="1">0.56</td>
                <td rowspan="1" colspan="1">0.55</td>
                <td rowspan="1" colspan="1">0.73</td>
                <td rowspan="1" colspan="1">0.63</td>
                <td rowspan="1" colspan="1">0.66</td>
                <td rowspan="1" colspan="1">0.63</td>
                <td rowspan="1" colspan="1">0.65</td>
                <td rowspan="1" colspan="1">0.74</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Carrs’ index</td>
                <td rowspan="1" colspan="1">85.19</td>
                <td rowspan="1" colspan="1">72.41</td>
                <td rowspan="1" colspan="1">70.12</td>
                <td rowspan="1" colspan="1">61.29</td>
                <td rowspan="1" colspan="1">60.00</td>
                <td rowspan="1" colspan="1">36.05</td>
                <td rowspan="1" colspan="1">29.03</td>
                <td rowspan="1" colspan="1">23.46</td>
                <td rowspan="1" colspan="1">25.00</td>
                <td rowspan="1" colspan="1">22.70</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Hausner ratio</td>
                <td rowspan="1" colspan="1">1.85</td>
                <td rowspan="1" colspan="1">1.72</td>
                <td rowspan="1" colspan="1">1.70</td>
                <td rowspan="1" colspan="1">1.61</td>
                <td rowspan="1" colspan="1">1.60</td>
                <td rowspan="1" colspan="1">1.36</td>
                <td rowspan="1" colspan="1">1.29</td>
                <td rowspan="1" colspan="1">1.23</td>
                <td rowspan="1" colspan="1">1.25</td>
                <td rowspan="1" colspan="1">1.23</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Angle of repose</td>
                <td rowspan="1" colspan="1">52.8</td>
                <td rowspan="1" colspan="1">51.0</td>
                <td rowspan="1" colspan="1">49.6</td>
                <td rowspan="1" colspan="1">47.2</td>
                <td rowspan="1" colspan="1">42.6</td>
                <td rowspan="1" colspan="1">36.4</td>
                <td rowspan="1" colspan="1">32.3</td>
                <td rowspan="1" colspan="1">30.1</td>
                <td rowspan="1" colspan="1">29.4</td>
                <td rowspan="1" colspan="1">27.8</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Flow according to <abbrev xlink:title="Carr’s index" id="ABBRID0EYMAE">CI</abbrev></td>
                <td rowspan="1" colspan="1">Very very poor</td>
                <td rowspan="1" colspan="1">Very very poor</td>
                <td rowspan="1" colspan="1">Very very poor</td>
                <td rowspan="1" colspan="1">Very very poor</td>
                <td rowspan="1" colspan="1">Very very poor</td>
                <td rowspan="1" colspan="1">Very poor</td>
                <td rowspan="1" colspan="1">Poor</td>
                <td rowspan="1" colspan="1">Passable</td>
                <td rowspan="1" colspan="1">Passable</td>
                <td rowspan="1" colspan="1">Passable</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Flow according to Hausner ratio</td>
                <td rowspan="1" colspan="1">Very very poor</td>
                <td rowspan="1" colspan="1">Very very poor</td>
                <td rowspan="1" colspan="1">Very very poor</td>
                <td rowspan="1" colspan="1">Very very poor</td>
                <td rowspan="1" colspan="1">Very poor</td>
                <td rowspan="1" colspan="1">Poor</td>
                <td rowspan="1" colspan="1">Passable</td>
                <td rowspan="1" colspan="1">Fair</td>
                <td rowspan="1" colspan="1">Fair</td>
                <td rowspan="1" colspan="1">Fair</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Flow according to Angle of repose</td>
                <td rowspan="1" colspan="1">Poor – must agitate or vibrate</td>
                <td rowspan="1" colspan="1">Poor – must agitate or vibrate</td>
                <td rowspan="1" colspan="1">Poor – must agitate or vibrate</td>
                <td rowspan="1" colspan="1">Poor – must agitate or vibrate</td>
                <td rowspan="1" colspan="1">Passable</td>
                <td rowspan="1" colspan="1">Fair</td>
                <td rowspan="1" colspan="1">Good</td>
                <td rowspan="1" colspan="1">Excellent</td>
                <td rowspan="1" colspan="1">Excellent</td>
                <td rowspan="1" colspan="1">Excellent</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec sec-type="Particle size distribution of the final blends" id="SECID0E4PAE">
        <title>Particle size distribution of the final blends</title>
        <p>The results of particle size distribution of each of the <abbrev xlink:title="direct compression" id="ABBRID0EDQAE">DC</abbrev>, <abbrev xlink:title="wet granulation" id="ABBRID0EHQAE">WG</abbrev> and <abbrev xlink:title="hot-melt extrusion" id="ABBRID0ELQAE">HME</abbrev> trials are shown in Table <xref ref-type="table" rid="T3">3</xref>. Since no particle size modification was employed in the <abbrev xlink:title="direct compression" id="ABBRID0ETQAE">DC</abbrev> process, two main peaks could be observed from the <abbrev xlink:title="Particle Size Distribution" id="ABBRID0EXQAE">PSD</abbrev> analysis. The first for the <abbrev xlink:title="Active Pharmaceutical Ingredients" id="ABBRID0E2QAE">API</abbrev> within the range of 10 microns and the other peak was for the rest of the composition around 200 microns. No significant changes on the <abbrev xlink:title="Particle Size Distribution" id="ABBRID0E6QAE">PSD</abbrev> were noticed after adding PEG4000. These results were endorsed by the bad physical characteristics of the blends for all the <abbrev xlink:title="direct compression" id="ABBRID0EDRAE">DC</abbrev> trials. On the other hand, the <abbrev xlink:title="wet granulation" id="ABBRID0EHRAE">WG</abbrev> and <abbrev xlink:title="hot-melt extrusion" id="ABBRID0ELRAE">HME</abbrev> trials resulted in a more homogeneous particle sizes distribution. As the quantity of the polymer used was increased, so did the size and homogeneity of the final blend.</p>
        <table-wrap id="T3" position="float" orientation="portrait">
          <label>Table 3.</label>
          <caption>
            <p>Particle size distribution of Cilostazol final blends.</p>
          </caption>
          <table id="TID0E6XAG" rules="all">
            <tbody>
              <tr>
                <th rowspan="1" colspan="1">Trial number</th>
                <th rowspan="1" colspan="1">D<sub>10</sub> (µm)</th>
                <th rowspan="1" colspan="1">D<sub>50</sub> (µm)</th>
                <th rowspan="1" colspan="1">D<sub>90</sub> (µm)</th>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>DC01</bold>
                </td>
                <td rowspan="1" colspan="1">3.18</td>
                <td rowspan="1" colspan="1">46.8</td>
                <td rowspan="1" colspan="1">256.0</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>DC04</bold>
                </td>
                <td rowspan="1" colspan="1">3.29</td>
                <td rowspan="1" colspan="1">46.3</td>
                <td rowspan="1" colspan="1">261.0</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>WG01</bold>
                </td>
                <td rowspan="1" colspan="1">6.42</td>
                <td rowspan="1" colspan="1">90.2</td>
                <td rowspan="1" colspan="1">316.0</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>WG02</bold>
                </td>
                <td rowspan="1" colspan="1">9.21</td>
                <td rowspan="1" colspan="1">100.0</td>
                <td rowspan="1" colspan="1">329.0</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>WG03</bold>
                </td>
                <td rowspan="1" colspan="1">13.7</td>
                <td rowspan="1" colspan="1">123.0</td>
                <td rowspan="1" colspan="1">362.0</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>WG04</bold>
                </td>
                <td rowspan="1" colspan="1">24.3</td>
                <td rowspan="1" colspan="1">135.0</td>
                <td rowspan="1" colspan="1">379.0</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>HME02</bold>
                </td>
                <td rowspan="1" colspan="1">20.1</td>
                <td rowspan="1" colspan="1">132.0</td>
                <td rowspan="1" colspan="1">374.0</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>HME03</bold>
                </td>
                <td rowspan="1" colspan="1">27.3</td>
                <td rowspan="1" colspan="1">145.0</td>
                <td rowspan="1" colspan="1">386.0</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec sec-type="Physical characteristics of the tablets" id="SECID0ERWAE">
        <title>Physical characteristics of the tablets</title>
        <p>The physical characteristics for the compressed tablets of each of <abbrev xlink:title="direct compression" id="ABBRID0EXWAE">DC</abbrev>, <abbrev xlink:title="wet granulation" id="ABBRID0E2WAE">WG</abbrev> and <abbrev xlink:title="hot-melt extrusion" id="ABBRID0E6WAE">HME</abbrev> formulations were recorded and they are summarized in the Table <xref ref-type="table" rid="T4">4</xref>. Tablets produced with <abbrev xlink:title="direct compression" id="ABBRID0EHXAE">DC</abbrev> method had sticking on the surface. There was a weight variation problem during the compression process. Tablets with weight that exceeded the allowable limits were excluded. The applied force for the compression was adjusted to get final tablets with hardness value around 100 N. This hardness value was granted for all the trials in order to avoid any effect of the tablets hardness upon the dissolution profile. Disintegration time of <abbrev xlink:title="direct compression" id="ABBRID0ELXAE">DC</abbrev> tablets was very fast and did not exceed one minute in most of the trials.</p>
        <table-wrap id="T4" position="float" orientation="portrait">
          <label>Table 4.</label>
          <caption>
            <p>Physical characteristics of the Cilostazol tablets.</p>
          </caption>
          <table id="TID0ED6AG" rules="all">
            <tbody>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">
                  <bold>Tablets weight (mg) n = 10</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>Tablet hardness (N) n = 4</bold>
                </td>
                <td rowspan="1" colspan="1">
                  <bold>Disintegration (min) n = 6</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>DC01</bold>
                </td>
                <td rowspan="1" colspan="1">301.6 ± 3.5</td>
                <td rowspan="1" colspan="1">99.3 ± 8.6</td>
                <td rowspan="1" colspan="1">0.50</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>DC02</bold>
                </td>
                <td rowspan="1" colspan="1">299.6 ± 3.5</td>
                <td rowspan="1" colspan="1">103.0 ± 5</td>
                <td rowspan="1" colspan="1">0.24</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>DC03</bold>
                </td>
                <td rowspan="1" colspan="1">302.9 ± 3.5</td>
                <td rowspan="1" colspan="1">99.9 ± 4</td>
                <td rowspan="1" colspan="1">0.50</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>DC04</bold>
                </td>
                <td rowspan="1" colspan="1">303.7 ± 6.1</td>
                <td rowspan="1" colspan="1">101.8 ± 7</td>
                <td rowspan="1" colspan="1">1.01</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>WG01</bold>
                </td>
                <td rowspan="1" colspan="1">300.3 ± 1.4</td>
                <td rowspan="1" colspan="1">102.8 ± 4.3</td>
                <td rowspan="1" colspan="1">0.34</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>WG02</bold>
                </td>
                <td rowspan="1" colspan="1">301.2 ± 1.7</td>
                <td rowspan="1" colspan="1">109.0 ± 4.1</td>
                <td rowspan="1" colspan="1">3.45</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>WG03</bold>
                </td>
                <td rowspan="1" colspan="1">301.3 ± 1.9</td>
                <td rowspan="1" colspan="1">105.3 ± 3.9</td>
                <td rowspan="1" colspan="1">8.05</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>WG04</bold>
                </td>
                <td rowspan="1" colspan="1">300.4 ± 1.3</td>
                <td rowspan="1" colspan="1">103.3 ± 3.8</td>
                <td rowspan="1" colspan="1">35.17</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>HME02</bold>
                </td>
                <td rowspan="1" colspan="1">300.4 ± 1.0</td>
                <td rowspan="1" colspan="1">104.8 ± 2.6</td>
                <td rowspan="1" colspan="1">11.00</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>HME03</bold>
                </td>
                <td rowspan="1" colspan="1">300.9 ± 1.9</td>
                <td rowspan="1" colspan="1">105.8 ± 3.3</td>
                <td rowspan="1" colspan="1">37.83</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Compressed tablets using <abbrev xlink:title="wet granulation" id="ABBRID0ET4AE">WG</abbrev> method without PEG4000 (WG01) suffered sticking issues, but the tablets weight was stable at the minimum speed of the compression machine. These tablets resulted in a fast disintegration time (~ 30 seconds). When <abbrev xlink:title="Polyethylene Glycol" id="ABBRID0EX4AE">PEG</abbrev> was incorporated, tablets produced in trials WG02, WG03 and WG04 were with good shining appearance and no sticking problem on the punches. Disintegration time varied depending on the quantity of the polymer used, and it was increasing exponentially with increasing the amount of the polymer (Table <xref ref-type="table" rid="T4">4</xref>).</p>
        <p>Tablets produced by the <abbrev xlink:title="hot-melt extrusion" id="ABBRID0EB5AE">HME</abbrev> technique were also with a good shining appearance and no sticking problems. Tablets weight during the compression was stable even at the maximum speed of the compression machine. Disintegration behavior was similar to that of the <abbrev xlink:title="wet granulation" id="ABBRID0EF5AE">WG</abbrev> tablets. Comparison of the disintegration time for tablets with the same composition produced by the three manufacturing techniques shows that <abbrev xlink:title="hot-melt extrusion" id="ABBRID0EJ5AE">HME</abbrev> tablets were always with the longest disintegration time.</p>
        <p>Overall, when using PEG4000, tablets produced by <abbrev xlink:title="hot-melt extrusion" id="ABBRID0EP5AE">HME</abbrev> had less thickness values compared to tablets with the same composition prepared by <abbrev xlink:title="wet granulation" id="ABBRID0ET5AE">WG</abbrev>. Disintegration time was slightly higher for <abbrev xlink:title="hot-melt extrusion" id="ABBRID0EX5AE">HME</abbrev> tablets when compared to similar formulations prepared by <abbrev xlink:title="wet granulation" id="ABBRID0E25AE">WG</abbrev>. As per the disintegration time, it increased almost four times at 20% PEG4000 trials when compared to 10% PEG4000 trials for both <abbrev xlink:title="hot-melt extrusion" id="ABBRID0E65AE">HME</abbrev> and <abbrev xlink:title="wet granulation" id="ABBRID0ED6AE">WG</abbrev> trials.</p>
      </sec>
      <sec sec-type="In-vitro dissolution results" id="SECID0EH6AE">
        <title>In-vitro dissolution results</title>
        <p>The most obvious impact of the manufacturing technique was on the dissolution of prepared tablets. The dissolution profiles for different trials were tested according to the dissolution test stated in the United State Pharmacopeia for Cilostazol tablets. As can be noticed in Fig. <xref ref-type="fig" rid="F2">2</xref>, different <abbrev xlink:title="direct compression" id="ABBRID0ER6AE">DC</abbrev> trials showed a fast release. However, it was noticed that none of the <abbrev xlink:title="direct compression" id="ABBRID0EV6AE">DC</abbrev> trials reached a full release profile at the end of the dissolution run time. This reflects that the incorporation of a hydrophilic polymer in the <abbrev xlink:title="direct compression" id="ABBRID0EZ6AE">DC</abbrev> technique had a low contribution to the dissolution of Cilostazol. F2 values between the standard formulation DC01 and the other <abbrev xlink:title="direct compression" id="ABBRID0E46AE">DC</abbrev> trails were &gt; 50; indicating that there are no significant differences even at the maximum level of PEG4000. Although the dissolution of <abbrev xlink:title="direct compression" id="ABBRID0ECAAG">DC</abbrev> tablets was satisfactory, the tablets prepared by this method suffered hampering weight variation and stickiness issues which rendered the technique unsuitable for further consideration.</p>
        <fig id="F2" position="float" orientation="portrait">
          <object-id content-type="doi">10.3897/pharmacia.68.e62465.figure2</object-id>
          <object-id content-type="arpha">FCCDC824-A852-5692-B3BB-531B45BF0C22</object-id>
          <label>Figure 2.</label>
          <caption>
            <p>Dissolution profiles of Cilostazol tablets prepared using various manufacturing techniques (Error bars represent the standard deviation, n = 6).</p>
          </caption>
          <graphic xlink:href="pharmacia-68-e62465-g002.jpg" position="float" orientation="portrait" xlink:type="simple" id="oo_511700.jpg">
            <uri content-type="original_file">https://binary.pensoft.net/fig/511700</uri>
          </graphic>
        </fig>
        <p>While being nonfunctional in the <abbrev xlink:title="direct compression" id="ABBRID0EUAAG">DC</abbrev> trials, the PEG4000 level had a significant influence on the release of the model drug from <abbrev xlink:title="wet granulation" id="ABBRID0EYAAG">WG</abbrev> and <abbrev xlink:title="hot-melt extrusion" id="ABBRID0E3AAG">HME</abbrev> tablets. Moreover, the tablets experienced different behaviors at different PEG4000 ratios with different manufacturing techniques. This behavior varied from enhancement to retardation of Cilostazol dissolution as compared to the <abbrev xlink:title="direct compression" id="ABBRID0EABAG">DC</abbrev> trails. Interestingly, the WG01 formulation with no PEG4000 showed a slow dissolution which did not exceed 80.0% of Cilostazol. The addition of 5.0% of PEG4000 enhanced the dissolution significantly with an average release of 96.7% at the end of the release. At this level, the release was as fast as those of the <abbrev xlink:title="direct compression" id="ABBRID0EEBAG">DC</abbrev> trials but with at least 10% more release at 60 minutes. Expectedly, the significant enhancement of the dissolution of Cilostazol was confirmed by an f2 value of 31.8 between WG01 and WG02 tablets. When the level of PEG4000 was increased to 10% (WG03), a retardation of the release rate could be seen as compared to WG02 but with an average release of 94% at 60 minutes. It is anticipated that the slow disintegration time in WG03 had contributed in the slow liberation of the <abbrev xlink:title="Active Pharmaceutical Ingredients" id="ABBRID0EIBAG">API</abbrev>. Nevertheless, the f2 value for WG03 versus WG01 was 43.3 indicating that it is still better than not to incorporate any polymer at all. The more polymer quantity used in WG04 (20% w/w PEG4000) resulted in a slower disintegration time and consequently in a slower release profile. At the end of the dissolution testing for WG04, it could be seen that the vessels contained small fragments of the tablets that were undissolved.</p>
        <p>The dissolution profiles for different <abbrev xlink:title="hot-melt extrusion" id="ABBRID0EOBAG">HME</abbrev> trials were also investigated. No standard formulation without PEG4000 or at 5% level can be obtained as the process of <abbrev xlink:title="hot-melt extrusion" id="ABBRID0ESBAG">HME</abbrev> implies to insert a polymeric molten material in enough quantities. Several attempts to extrude the 5% PEG4000 formulation were investigated with some modifications to the temperatures of the different zones of the extruder and on the rotation speed of the screw. Nevertheless, the blend was with poor extrudability due to the inconvenient flow of the molten polymer with the <abbrev xlink:title="Active Pharmaceutical Ingredients" id="ABBRID0EWBAG">API</abbrev>: Lactose Monohydrate mixture inside the barrel. HME02 extrudates was extruded slowly with a clay-appearance, while HME03 was extruded smoothly as per the processing parameters specified in the methods section.</p>
        <p>For trials with PEG4000 at 10%, HME02 had exceeded the other trials and had given a 90% release at 30 minutes in spite of the slow start. This slow start can be explained by the slow disintegration of tablets in HME02 and to a less extent in WG03. Once HME02 tablets disintegrated, they eluted Cilostazol quickly compared to WG03 and DC03. At the end of the dissolution runs, both HME02 and WG03 had almost a full release of the <abbrev xlink:title="Active Pharmaceutical Ingredients" id="ABBRID0E3BAG">API</abbrev> while it was only 86% for DC03. This can be understood as the homogeneity of the polymer distribution and spreading was better by the <abbrev xlink:title="hot-melt extrusion" id="ABBRID0EACAG">HME</abbrev> technique followed by <abbrev xlink:title="wet granulation" id="ABBRID0EECAG">WG</abbrev> and worst for the <abbrev xlink:title="direct compression" id="ABBRID0EICAG">DC</abbrev> technique.</p>
        <p>On the other hand, adding 20% of PEG4000 slowed down the dissolution in trial HME03 without a full release of the <abbrev xlink:title="Active Pharmaceutical Ingredients" id="ABBRID0EOCAG">API</abbrev> at 60 minutes. Tablets in dissolution vessels were observed with an almost unchanged shape for the first 30 minutes of the dissolution run. HME03 tablets disintegrated very slowly; they needed 38 minutes to be fully disintegrated in the disintegration tester (Table <xref ref-type="table" rid="T4">4</xref>). It is believed that 20% of PEG4000 had formed a hydrophilic matrix in tablets of trial HME03 and to lower extent in WG04, thus Cilostazol eluted slower in the trial HME03 than that of WG04. This can be understood as <abbrev xlink:title="hot-melt extrusion" id="ABBRID0EWCAG">HME</abbrev> distributed PEG4000 more efficiently than <abbrev xlink:title="wet granulation" id="ABBRID0E1CAG">WG</abbrev> and therefore, the hydrophilic matrix that sustained the release in HME03 was more efficient in that aspect than it in WG04. When compared to the trials with 10% PEG4000, <abbrev xlink:title="hot-melt extrusion" id="ABBRID0E5CAG">HME</abbrev> and <abbrev xlink:title="wet granulation" id="ABBRID0ECDAG">WG</abbrev> with 20% PEG4000 had a slower release profile. Although HME03 had a slower release compared to WG04, f2 value revealed some kind of similarity between the dissolution profiles of HME03 and WG04 (f2 value 54.1).</p>
      </sec>
      <sec sec-type="Differential scanning calorimetry" id="SECID0EGDAG">
        <title>Differential scanning calorimetry</title>
        <p>Among other techniques, <abbrev xlink:title="differential scanning calorimetry" id="ABBRID0EMDAG">DSC</abbrev> is beneficial in the characterization of the solid state of the drug in extrudates (<xref ref-type="bibr" rid="B5">Censi et al. 2018</xref>). To set a reference point, <abbrev xlink:title="differential scanning calorimetry" id="ABBRID0EUDAG">DSC</abbrev> testing for Cilostazol, Lactose Monohydrate and a combination of Cilostazol: Lactose Monohydrate (2:1) were done separately in order to standardize any possible changes after the different manufacturing processes. Cilostazol showed a main endothermic peak at 159 °C, while Lactose Monohydrate showed two main endothermic peaks; one of them represents the dehydration of Lactose at 145 °C and the other is at 218 °C and represents the melting of Lactose (<xref ref-type="bibr" rid="B15">Raut et al. 2011</xref>). The melting of Lactose was beyond the studied range for other trials as the important peaks were for the <abbrev xlink:title="Active Pharmaceutical Ingredients" id="ABBRID0E3DAG">API</abbrev> and PEG4000, where all of them were below 200 °C. The mixture of Cilostazol and Lactose Monohydrate showed two main peaks without any changes (Figure <xref ref-type="fig" rid="F3">3</xref>) . In addition, <abbrev xlink:title="differential scanning calorimetry" id="ABBRID0EEEAG">DSC</abbrev> testing was done to PEG4000. A main endothermic peak was observed at 64 °C for PEG4000 as seen in Fig. <xref ref-type="fig" rid="F3">3</xref>.</p>
        <fig id="F3" position="float" orientation="portrait">
          <object-id content-type="doi">10.3897/pharmacia.68.e62465.figure3</object-id>
          <object-id content-type="arpha">5A9085D9-FCDF-55F3-B78F-3C4CEDE7BF22</object-id>
          <label>Figure 3.</label>
          <caption>
            <p><abbrev xlink:title="differential scanning calorimetry" id="ABBRID0EUEAG">DSC</abbrev> scans of raw materials as well as Cilostazol: Lactose Monohydrate at the ratio used in preparing the tablets by various manufacturing techniques (Table <xref ref-type="table" rid="T1">1</xref>).</p>
          </caption>
          <graphic xlink:href="pharmacia-68-e62465-g003.jpg" position="float" orientation="portrait" xlink:type="simple" id="oo_511701.jpg">
            <uri content-type="original_file">https://binary.pensoft.net/fig/511701</uri>
          </graphic>
        </fig>
        <p><abbrev xlink:title="differential scanning calorimetry" id="ABBRID0EDFAG">DSC</abbrev> testing for the trials DC04, WG04 and HME03 was undertaken as these trials contain the maximum amount of PEG4000. The <abbrev xlink:title="differential scanning calorimetry" id="ABBRID0EHFAG">DSC</abbrev> patterns showed no significant changes on any of the materials regarding the place or the intensity/weight ratios of the PEG4000 and Cilostazol peaks as observed in Figure <xref ref-type="fig" rid="F4">4</xref>. A gradual change in the onset of Lactose dehydration peak was noticed, in a matter that is dependent on the different formulation processes. The peak of Lactose Monohydrate dehydration appeared to be broader and shallower at HME03 when compared to WG04 and DC04 which may be attributed to partial dehydration of lactose monohydrate during the <abbrev xlink:title="hot-melt extrusion" id="ABBRID0EPFAG">HME</abbrev> process.</p>
        <fig id="F4" position="float" orientation="portrait">
          <object-id content-type="doi">10.3897/pharmacia.68.e62465.figure4</object-id>
          <object-id content-type="arpha">BEE04CA8-8B44-5933-A6AA-0E5FD46CE5D9</object-id>
          <label>Figure 4.</label>
          <caption>
            <p><abbrev xlink:title="differential scanning calorimetry" id="ABBRID0E2FAG">DSC</abbrev> scans of Cilostazol: Lactose Monohydrate: PEG4000 (1) extrudates, (2) <abbrev xlink:title="wet granulation" id="ABBRID0E6FAG">WG</abbrev> intragranular components and (3) <abbrev xlink:title="direct compression" id="ABBRID0EDGAG">DC</abbrev> physical mixture, at 20% level of PEG4000.</p>
          </caption>
          <graphic xlink:href="pharmacia-68-e62465-g004.jpg" position="float" orientation="portrait" xlink:type="simple" id="oo_511702.jpg">
            <uri content-type="original_file">https://binary.pensoft.net/fig/511702</uri>
          </graphic>
        </fig>
        <p>In summary, this work has clarified how the different manufacturing technologies had contributed to Cilostazol dissolution without changing the crystalline form of the <abbrev xlink:title="Active Pharmaceutical Ingredients" id="ABBRID0EOGAG">API</abbrev>. Unlike the <abbrev xlink:title="direct compression" id="ABBRID0ESGAG">DC</abbrev> trials which were found with no significant differences, <abbrev xlink:title="wet granulation" id="ABBRID0EWGAG">WG</abbrev> and <abbrev xlink:title="hot-melt extrusion" id="ABBRID0E1GAG">HME</abbrev> showed contrasting enhancement and retardation effects regarding the dissolution profile of Cilostazol tablets in a matter that is dependent on the type and quantity of PEG4000 polymer used. Inserting 5% of PEG4000 in <abbrev xlink:title="wet granulation" id="ABBRID0E5GAG">WG</abbrev> had resulted in tablets with a fast dissolution profile. <abbrev xlink:title="hot-melt extrusion" id="ABBRID0ECHAG">HME</abbrev> with 10% polymer had resulted in a faster dissolution profile compared to <abbrev xlink:title="wet granulation" id="ABBRID0EGHAG">WG</abbrev> trials with similar quantities of polymers. The suggested interpretation for the dissolution enhancement at certain concentrations of PEG4000 was referred to a better distribution of the polymer throughout the blends; consequently, better wetting and solubilization. The more quantity of PEG4000 polymer inserted in <abbrev xlink:title="wet granulation" id="ABBRID0EKHAG">WG</abbrev> and <abbrev xlink:title="hot-melt extrusion" id="ABBRID0EOHAG">HME</abbrev>, the slower the dissolution profile was. Long disintegration times for trials with 20% w/w of PEG4000 endorsed this observation. These effects are not related to changes in the solid-state changes of Cilostazol as confirmed by <abbrev xlink:title="differential scanning calorimetry" id="ABBRID0ESHAG">DSC</abbrev>. Overall, the use of the hydrophilic polymer at optimum concentrations was useful as a wetting agent for developing formulations with better dissolution profile.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>All the materials were kindly donated by Tabuk Pharmaceutical Research Company (Amman, Jordan).</p>
      <p>Authors are grateful to the Applied Science Private University, Amman, Jordan for the full financial support granted to this research project.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Albers</surname><given-names>J</given-names></name><name name-style="western"><surname>Alles</surname><given-names>R</given-names></name><name name-style="western"><surname>Matthée</surname><given-names>K</given-names></name><name name-style="western"><surname>Knop</surname><given-names>K</given-names></name><name name-style="western"><surname>Nahrup</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kleinebudde</surname><given-names>P</given-names></name></person-group> (<year>2009</year>) <article-title>Mechanism of drug release from polymethacrylate-based extrudates and milled strands prepared by hot-melt extrusion.</article-title><source>European Journal of Pharmaceutics and Biopharmaceutics</source><volume>71</volume>(<issue>2</issue>): <fpage>387</fpage>–<lpage>394</lpage>. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1016/j.ejpb.2008.10.002">https://doi.org/10.1016/j.ejpb.2008.10.002</ext-link></mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Aljaberi</surname><given-names>A</given-names></name><name name-style="western"><surname>Chatterji</surname><given-names>A</given-names></name><name name-style="western"><surname>Shah</surname><given-names>NH</given-names></name><name name-style="western"><surname>Sandhu</surname><given-names>HK</given-names></name></person-group> (<year>2009</year>) <article-title>Functional performance of silicified microcrystalline cellulose versus microcrystalline cellulose: a case study.</article-title><source>Drug development and industrial pharmacy</source><volume>35</volume>(<issue>9</issue>): <fpage>1066</fpage>–<lpage>1071</lpage>. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1080/03639040902774131">https://doi.org/10.1080/03639040902774131</ext-link></mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Aljaberi</surname><given-names>A</given-names></name><name name-style="western"><surname>Chatterji</surname><given-names>A</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shah</surname><given-names>NH</given-names></name><name name-style="western"><surname>Malick</surname><given-names>W</given-names></name><name name-style="western"><surname>Singhal</surname><given-names>D</given-names></name><name name-style="western"><surname>Sandhu</surname><given-names>HK</given-names></name></person-group> (<year>2013a</year>) <article-title>Understanding and optimizing the dual excipient functionality of sodium lauryl sulfate in tablet formulation of poorly water soluble drug: wetting and lubrication.</article-title><source>Pharmaceutical development and technology</source><volume>18</volume>(<issue>2</issue>): <fpage>490</fpage>–<lpage>503</lpage>. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.3109/10837450.2012.723717">https://doi.org/10.3109/10837450.2012.723717</ext-link></mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Aljaberi</surname><given-names>A</given-names></name><name name-style="western"><surname>Ardakani</surname><given-names>A</given-names></name><name name-style="western"><surname>Khdair</surname><given-names>A</given-names></name><name name-style="western"><surname>Abdel-Rahim</surname><given-names>SA</given-names></name><name name-style="western"><surname>Meqdadi</surname><given-names>E</given-names></name><name name-style="western"><surname>Ayyash</surname><given-names>M</given-names></name><name name-style="western"><surname>Alobaidi</surname><given-names>GM</given-names></name><name name-style="western"><surname>Al-Zoubi</surname><given-names>N</given-names></name></person-group> (<year>2013b</year>) <article-title>Tableting functionality evaluation of Prosolv Easytab in comparison to physical mixtures of its individual components.</article-title><source>Journal of Drug Delivery Science and Technology</source><volume>23</volume>: <fpage>499</fpage>–<lpage>504</lpage>. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1016/S1773-2247(13)50072-4">https://doi.org/10.1016/S1773-2247(13)50072-4</ext-link></mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Censi</surname><given-names>R</given-names></name><name name-style="western"><surname>Gigliobianco</surname><given-names>MR</given-names></name><name name-style="western"><surname>Casadidio</surname><given-names>C</given-names></name><name name-style="western"><surname>Di Martino</surname><given-names>P</given-names></name></person-group> (<year>2018</year>) Hot melt extrusion: Highlighting physicochemical factors to be investigated while designing and optimizing a hot melt extrusion process. Pharmaceutics 10(3): e89. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.3390/pharmaceutics10030089">https://doi.org/10.3390/pharmaceutics10030089</ext-link></mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Hashim</surname><given-names>II</given-names></name><name name-style="western"><surname>Ghazy</surname><given-names>NF</given-names></name><name name-style="western"><surname>El-Shabouri</surname><given-names>MH</given-names></name></person-group> (<year>2015</year>) <article-title>Potential use of phospholipids in combination with hydrophilic carriers for enhancement of the dissolution and oral bioavailability of imidazole antifungal class II drugs.</article-title><source>Die Pharmazie – An International Journal of Pharmaceutical Sciences</source><volume>70</volume>(<issue>11</issue>): <fpage>706</fpage>–<lpage>715</lpage>. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1691/ph.2015.5079">https://doi.org/10.1691/ph.2015.5079</ext-link></mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Kalepu</surname><given-names>S</given-names></name><name name-style="western"><surname>Nekkanti</surname><given-names>V</given-names></name></person-group> (<year>2015</year>) <article-title>Insoluble drug delivery strategies: review of recent advances and business prospects.</article-title><source>Acta Pharmaceutica Sinica B</source><volume>5</volume>(<issue>5</issue>): <fpage>442</fpage>–<lpage>453</lpage>. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1016/j.apsb.2015.07.003">https://doi.org/10.1016/j.apsb.2015.07.003</ext-link></mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Kalivoda</surname><given-names>A</given-names></name><name name-style="western"><surname>Fischbach</surname><given-names>M</given-names></name><name name-style="western"><surname>Kleinebudde</surname><given-names>P</given-names></name></person-group> (<year>2012</year>) <article-title>Application of mixtures of polymeric carriers for dissolution enhancement of oxeglitazar using hot-melt extrusion.</article-title><source>International journal of pharmaceutics</source><volume>439</volume>(<issue>1–2</issue>): <fpage>145</fpage>–<lpage>156</lpage>. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1016/j.ijpharm.2012.10.013">https://doi.org/10.1016/j.ijpharm.2012.10.013</ext-link></mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Leuner</surname><given-names>C</given-names></name><name name-style="western"><surname>Dressman</surname><given-names>J</given-names></name></person-group> (<year>2000</year>) <article-title>Improving drug solubility for oral delivery using solid dispersions.</article-title><source>European journal of Pharmaceutics and Biopharmaceutics</source><volume>50</volume>(<issue>1</issue>): <fpage>47</fpage>–<lpage>60</lpage>. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1016/S0939-6411(00)00076-X">https://doi.org/10.1016/S0939-6411(00)00076-X</ext-link></mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Maniruzzaman</surname><given-names>M</given-names></name><name name-style="western"><surname>Boateng</surname><given-names>JS</given-names></name><name name-style="western"><surname>Snowden</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Douroumis</surname><given-names>D</given-names></name></person-group> (<year>2012</year>) A review of hot-melt extrusion: process technology to pharmaceutical products. International Scholarly Research Notices 2012: 436763. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.5402/2012/436763">https://doi.org/10.5402/2012/436763</ext-link></mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Patel</surname><given-names>R</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M</given-names></name></person-group> (<year>2008</year>) <article-title>Preparation, characterization, and dissolution behavior of a solid dispersion of simvastatin with polyethylene glycol 4000 and polyvinylpyrrolidone K30.</article-title><source>Journal of dispersion science and technology</source><volume>29</volume>(<issue>2</issue>): <fpage>193</fpage>–<lpage>204</lpage>. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1080/01932690701706946">https://doi.org/10.1080/01932690701706946</ext-link></mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Patel</surname><given-names>RP</given-names></name><name name-style="western"><surname>Patel</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Bhimani</surname><given-names>DB</given-names></name><name name-style="western"><surname>Patel</surname><given-names>JK</given-names></name></person-group> (<year>2008</year>) <article-title>Physicochemical characterization and dissolution study of solid dispersions of furosemide with polyethylene glycol 6000 and polyvinylpyrrolidone K30.</article-title><source>Dissolution Technologies</source><volume>15</volume>(<issue>3</issue>): <fpage>17</fpage>–<lpage>25</lpage>. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.14227/DT150308P17">https://doi.org/10.14227/DT150308P17</ext-link></mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Patil</surname><given-names>H</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>RV</given-names></name><name name-style="western"><surname>Repka</surname><given-names>MA</given-names></name></person-group> (<year>2016</year>) <article-title>Hot-melt extrusion: from theory to application in pharmaceutical formulation.</article-title><source>AAPS Pharmscitech</source><volume>17</volume>(<issue>1</issue>): <fpage>20</fpage>–<lpage>42</lpage>. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1208/s12249-015-0360-7">https://doi.org/10.1208/s12249-015-0360-7</ext-link></mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Pinho</surname><given-names>LA</given-names></name><name name-style="western"><surname>Souza</surname><given-names>SG</given-names></name><name name-style="western"><surname>Marreto</surname><given-names>RN</given-names></name><name name-style="western"><surname>Sa-Barreto</surname><given-names>LL</given-names></name><name name-style="western"><surname>Gratieri</surname><given-names>T</given-names></name><name name-style="western"><surname>Gelfuso</surname><given-names>GM</given-names></name><name name-style="western"><surname>Cunha-Filho</surname><given-names>M</given-names></name></person-group> (<year>2018</year>) Dissolution enhancement in cocoa extract, combining hydrophilic polymers through hot-melt extrusion. Pharmaceutics 10(3): e135. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.3390/pharmaceutics10030135">https://doi.org/10.3390/pharmaceutics10030135</ext-link></mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Raut</surname><given-names>DM</given-names></name><name name-style="western"><surname>Allada</surname><given-names>R</given-names></name><name name-style="western"><surname>Pavan</surname><given-names>KV</given-names></name><name name-style="western"><surname>Deshpande</surname><given-names>G</given-names></name><name name-style="western"><surname>Patil</surname><given-names>D</given-names></name><name name-style="western"><surname>Patil</surname><given-names>A</given-names></name><name name-style="western"><surname>Deshmukh</surname><given-names>A</given-names></name><name name-style="western"><surname>Raut</surname><given-names>DM</given-names></name><name name-style="western"><surname>Sakharkar</surname><given-names>DM</given-names></name><name name-style="western"><surname>Bodke</surname><given-names>PS</given-names></name><name name-style="western"><surname>Mahajan</surname><given-names>DT</given-names></name></person-group> (<year>2011</year>) <article-title>Dehydration of lactose monohydrate: analytical and physical characterization.</article-title><source>Der Pharmacia Lettre</source><volume>3</volume>(<issue>5</issue>): <fpage>202</fpage>–<lpage>212</lpage>. <ext-link xlink:type="simple" ext-link-type="uri" xlink:href="https://www.researchgate.net/profile/Dr_Pavan_Kommavarapu/publication/265376074_Dehydration_of_Lactose_Monohydrate_Analytical_and_Physical_Characterization/links/5409dfa50cf2f2b29a2cc7c5/Dehydration-of-Lactose-Monohydrate-Analytical-and-Physical-Characterization.pdf">https://www.researchgate.net/profile/Dr_Pavan_Kommavarapu/publication/265376074_Dehydration_of_Lactose_Monohydrate_Analytical_and_Physical_Characterization/links/5409dfa50cf2f2b29a2cc7c5/Dehydration-of-Lactose-Monohydrate-Analytical-and-Physical-Characterization.pdf</ext-link></mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Regev</surname><given-names>G</given-names></name><name name-style="western"><surname>Patel</surname><given-names>SK</given-names></name><name name-style="western"><surname>Moncla</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Twist</surname><given-names>J</given-names></name><name name-style="western"><surname>Devlin</surname><given-names>B</given-names></name><name name-style="western"><surname>Rohan</surname><given-names>LC</given-names></name></person-group> (<year>2019</year>) Novel Application of Hot Melt Extrusion for the Manufacturing of Vaginal Films Containing Microbicide Candidate Dapivirine. AAPS PharmSciTech 20(6): e239. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1208/s12249-019-1442-8">https://doi.org/10.1208/s12249-019-1442-8</ext-link></mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Ren</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mei</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Guo</surname><given-names>G</given-names></name></person-group> (<year>2019</year>) Recent perspectives in hot melt extrusion-based polymeric formulations for drug delivery: applications and innovations. AAPS PharmSciTech 20(3): e92. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1208/s12249-019-1300-8">https://doi.org/10.1208/s12249-019-1300-8</ext-link></mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Repka</surname><given-names>MA</given-names></name><name name-style="western"><surname>Majumdar</surname><given-names>S</given-names></name><name name-style="western"><surname>Kumar Battu</surname><given-names>S</given-names></name><name name-style="western"><surname>Srirangam</surname><given-names>R</given-names></name><name name-style="western"><surname>Upadhye</surname><given-names>SB</given-names></name></person-group> (<year>2008</year>) <article-title>Applications of hot-melt extrusion for drug delivery.</article-title><source>Expert opinion on drug delivery</source><volume>5</volume>(<issue>12</issue>): <fpage>1357</fpage>–<lpage>1376</lpage>. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1517/17425240802583421">https://doi.org/10.1517/17425240802583421</ext-link></mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Sanoufi</surname><given-names>MR</given-names></name><name name-style="western"><surname>Aljaberi</surname><given-names>A</given-names></name><name name-style="western"><surname>Hamdan</surname><given-names>I</given-names></name><name name-style="western"><surname>Al-Zoubi</surname><given-names>N</given-names></name></person-group> (<year>2020</year>) <article-title>The use of design of experiments to develop hot melt extrudates for extended release of diclofenac sodium.</article-title><source>Pharmaceutical Development and Technology</source><volume>25</volume>(<issue>2</issue>): <fpage>187</fpage>–<lpage>196</lpage>. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1080/10837450.2019.1684519">https://doi.org/10.1080/10837450.2019.1684519</ext-link></mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Tang</surname><given-names>B</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Fang</surname><given-names>G</given-names></name><name name-style="western"><surname>Song</surname><given-names>H</given-names></name></person-group> (<year>2019</year>) Development and evaluation of synchronized and sustained release Tripergium Wilfordii tablets based hot-melt extrusion and direct powder compression. Journal of Drug Delivery Science and Technology 53: e101208. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1016/j.jddst.2019.101208">https://doi.org/10.1016/j.jddst.2019.101208</ext-link></mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Weatherley</surname><given-names>S</given-names></name><name name-style="western"><surname>Mu</surname><given-names>B</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>MR</given-names></name><name name-style="western"><surname>Sheskey</surname><given-names>PJ</given-names></name><name name-style="western"><surname>O’Donnell</surname><given-names>KP</given-names></name></person-group> (<year>2013</year>) <article-title>Hot-melt granulation in a twin screw extruder: effects of processing on formulations with caffeine and ibuprofen.</article-title><source>Journal of pharmaceutical sciences</source><volume>102</volume>(<issue>12</issue>): <fpage>4330</fpage>–<lpage>4336</lpage>. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1002/jps.23739">https://doi.org/10.1002/jps.23739</ext-link></mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sunada</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>QF</given-names></name></person-group> (<year>2007</year>) <article-title>Improvement of dissolution rate of arbidol hydrochloride from solid dispersion prepared with PEG system by fusion method.</article-title><source>Journal of drug delivery science and technology</source><volume>17</volume>(<issue>2</issue>): <fpage>145</fpage>–<lpage>148</lpage>. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1016/S1773-2247(07)50022-5">https://doi.org/10.1016/S1773-2247(07)50022-5</ext-link></mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>G</given-names></name><name name-style="western"><surname>Dong</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X</given-names></name></person-group> (<year>2019</year>) Development of ibuprofen dry suspensions by hot melt extrusion: Characterization, physical stability and pharmacokinetic studies. Journal of Drug Delivery Science and Technology 54: e101313. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1016/j.jddst.2019.101313">https://doi.org/10.1016/j.jddst.2019.101313</ext-link></mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation xlink:type="simple"><person-group><name name-style="western"><surname>Zi</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Ju</surname><given-names>C</given-names></name><name name-style="western"><surname>Su</surname><given-names>Z</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name></person-group> (<year>2019</year>) <article-title>Solubility and bioavailability enhancement study of lopinavir solid dispersion matrixed with a polymeric surfactant-Soluplus.</article-title><source>European Journal of Pharmaceutical Sciences</source><volume>134</volume>: <fpage>233</fpage>–<lpage>245</lpage>. <ext-link xlink:type="simple" ext-link-type="doi" xlink:href="10.1016/j.ejps.2019.04.022">https://doi.org/10.1016/j.ejps.2019.04.022</ext-link></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
